Non-alcoholic steatohepatitis with normal aminotransferase values

Table 1 Anthropometric, clinical and laboratory features of all NAFLD cases according to liver enzyme levels n (%)

	According to liver enzyme levels (n = 34)		P
	Normal liver enzyme (n = 9)	Elevated liver enzyme (n = 25)
Age (yr)	52.0 ± 6.16	49.8 ± 6.77	> 0.05
Gender (male/female)	1/8 (11.2/88.8)	10/15 (40/60)	> 0.05
Hepatomegaly	4 (44.4)	7 (28.0)	> 0.05
BMI (kg/m2)
Normal weight	0 (0)	1 (4)	> 0.05
Overweight	0 (0)	2 (8)	> 0.05
Obese	7 (77.8)	20 (80.0)	> 0.05
Morbid obese	2 (22.2)	2 (8.0)	> 0.05
Waist/hip ratio	6 (66.7)	19 (76.0)	> 0.05
Systolic blood pressure (mmHg)1	130 (110-150)	120 (110-180)	> 0.05
Diastolic blood pressure (mmHg)1	76 (60-90)	70 (60-120)	> 0.05
Hypertension	4 (44.4)	12 (48.0)	> 0.05
HDL-Cholesterol (mg/dL)	43.56 ± 7.99	45.52 ± 7.04	> 0.05
Low-HDL level	6 (66.7)	11 (44.0)	> 0.05
Triglycerides (mg/dL)1	187 (43-360)	125 (39-304)	> 0.05
Hypertriglyceridemia	7 (77.8)	8 (32.0)	< 0.05
Fasting glucose (mg/dL)1	101 (73-164)	101 (87-195)	> 0.05
Diabetes	2 (22.2)	6 (24.0)	> 0.05
Impaired glucose tolerance	3 (33.3)	7 (28.0)	> 0.05
Fasting insulin (&mgr;U/mL)1	11.8 (6-23.66)	15.23 (4.76-47.3)	> 0.05
Insulin resistance-HOMA-IR	2 (22.2)	14 (56.0)	> 0.05
AST (IU/L)1	17 (14-29)	49 (33-92)	< 0.05
ALT (IU/L)1	13 (13-33)	81 (32-166)	< 0.05
GGT (IU/L)1	19 (15-33)	42 (15-426)	< 0.05
ALP (IU/L)1	96 (52-113)	81 (51-154)	> 0.05
NASH	7 (77.7)	16 (64.0)	> 0.05
Metabolic syndrome	8 (88.8)	19 (76)	> 0.05

¹Data expressed as median (minimum-maximum); BMI: Body mass index; HDL: High-density lipoprotein; ALP: Alkaline phosphatase; GGT: Gamma glutamyl transpeptidase. Only the prevalence of hyperglyceridemia in NAFLD patients with normal liver enzyme levels was higher than in those with elevated liver enzyme.